Vigil Neuro
Jonathan Houze is currently the Head of Chemistry at Vigil Neuroscience. Previously, Jonathan held the title of Director, Research at Amgen for over 15 years, where Jonathan led various programs against cardiovascular disease, pain, and neurodegenerative disease. With extensive experience in medicinal chemistry, Jonathan has been involved in the development and delivery of multiple clinical candidates, including compounds evaluated in Phase I and Phase II clinical trials. Jonathan's expertise and leadership skills have been instrumental in driving successful research collaborations and licensing deals throughout their career.
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.